Across TCGA pan-cancer cohorts, SPDYE17 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SPDYE17’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where SPDYE17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SPDYE17 is over-expressed in tumor.

BRCA, LIHC, and KIRC are the cancer types where SPDYE17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPDYE17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	+0.070	.041	2	view →
LIHC	Female	All	+0.030	.025	1	view →
KIRC	All	All	+0.015	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SPDYE17 RNA expression & survival · all SPDYE17 data types